Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
In-hospital mortality rate lower for patients with acute heart failure exacerbation who received colchicine for gout flare
Increased uric acid excretion could explain, at least in part, the renoprotective effects of SGLT2 inhibitors.
A study conducted in Taiwan is the first to show that hyperuricemia is as risky as diabetes in contributing to ESKD and death risk in patients with stage 3 to 5 CKD.
Investigators compared the long-term effects of febuxostat on arterial stiffness and atherosclerosis in patients with hyperuricemia and gout.
John Botson, MD, provides his perspective on including immunodulatory therapy in combination with pegloticase and encourages clinicians to evolve their standard of care in the treatment of uncontrolled gout.
Colchicine, a plant-derived alkaloid, has a broad range of anti-inflammatory effects that interfere with neutrophil function, according to investigators.
Researchers determined risk for gout flares and the effect of colchicine prophylaxis on flares following COVID-19 vaccination.
Nearly 24% of patients with advanced CKD, including those on dialysis, have gout, according to a study.
In recognition of American Heart Month 2022, Jasvinder Singh, MD, evaluates the association between gout and cardiac disease, based on published literature.